The bromodomain: From epigenome reader to druggable target

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 8, 2014, Pages 676-685

  Sanchez, Roberto ^a   Meslamani, Jamel ^a   Zhou, Ming Ming ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bromodomain; Gene transcription; Small molecule inhibitors

Indexed keywords

CELL PROTEIN; LYSINE; PROTEIN INHIBITOR; SMALL MOLECULE INHIBITOR; UNCLASSIFIED DRUG;

CHROMATIN STRUCTURE; DRUG TARGETING; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; INFLAMMATION; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

BROMODOMAIN; GENE TRANSCRIPTION; SMALL MOLECULE INHIBITORS;

ACETYLATION; CARDIOVASCULAR DISEASES; EPIGENESIS, GENETIC; HISTONES; HIV INFECTIONS; HUMANS; LYSINE; MODELS, MOLECULAR; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84904054123     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.03.011     Document Type: Review

References (113)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705.
2. Turner B.M. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat. Struct. Mol. Biol. 2005, 12(2):110-112.
3. Tan M., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146(6):1016-1028.
4. Jenuwein T., Allis C. Translating the histone code. Science 2001, 293(5532):1074-1080.
5. Turner B. Cellular memory and the histone code. Cell 2002, 111(3):285-291.
6. Nightingale K., O'Neill L., Turner B. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 2006, 16(2):125-136.
7. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. U. S. A. 1964, 51:786-794.
8. Turner B. Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell. Mol. Life Sci. 1998, 54(1):21-31.
9. Berger S. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 2002, 12(2):142-148.
10. Neely K., Workman J. Histone acetylation and chromatin remodeling: which comes first?. Mol. Genet. Metab. 2002, 76(1):1-5.
11. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(5942):834-840.
12. Zhao S., et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327(5968):1000-1004.
13. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. EMBO J. 2000, 19(6):1176-1179.
14. You L., et al. Lysine acetylation: enzymes, bromodomains and links to different diseases. Essays Biochem. 2012, 52:1-12.
15. Zeng L., Zhou M. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 2002, 513(1):124-128.
16. Arrowsmith C.H., et al. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11(5):384-400.
17. Barbieri I., Cannizzaro E., Dawson M.A. Bromodomains as therapeutic targets in cancer. Brief Funct. Genomics 2013, 12(3):219-230.
18. Boehm D., Conrad R.J., Ott M. Bromodomain proteins in HIV infection. Viruses 2013, 5(6):1571-1586.
19. Prinjha R.K., Witherington J., Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol. Sci. 2012, 33(3):146-153.
20. Zhang G., Sanchez R., Zhou M.M. Scaling the druggability landscape of human bromodomains, a new class of drug targets. J. Med. Chem. 2012, 55(17):7342-7345.
21. Dhalluin C., et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399(6735):491-496.
22. Mujtaba S., Zeng L., Zhou M. Structure and acetyl-lysine recognition of the bromodomain. Oncogene 2007, 26(37):5521-5527.
23. Filippakopoulos P., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149(1):214-231.
24. Jeanmougin F., et al. The bromodomain revisited. Trends Biochem. Sci. 1997, 22(5):151-153.
25. Mujtaba S., et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 2004, 13(2):251-263.
26. Plotnikov A.N., et al. Structural insights into acetylated-histone H4 recognition by the bromodomain-PHD finger module of human transcriptional coactivator CBP. Structure 2014, 22(2):353-360.
27. Zeng L., et al. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. Structure 2008, 16(4):643-652.
28. Owen D., et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000, 19(22):6141-6149.
29. Zeng L., et al. Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing. Nat. Struct. Mol. Biol. 2008, 15(6):626-633.
30. Moriniere J., et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009, 461(7264):664-668.
31. Gamsjaeger R., et al. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 2011, 31(13):2632-2640.
32. Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS Lett. 2012, 586(17):2692-2704.
33. Charlop-Powers Z., et al. Structural insights into selective histone H3 recognition by the human Polybromo bromodomain 2. Cell Res. 2010, 20(5):529-538.
34. Umehara T., et al. Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 2010, 285(10):7610-7618.
35. Basu M.K., et al. Evolution of protein domain promiscuity in eukaryotes. Genome Res. 2008, 18(3):449-461.
36. Basu M.K., Poliakov E., Rogozin I.B. Domain mobility in proteins: functional and evolutionary implications. Brief. Bioinform. 2009, 10(3):205-216.
37. Sanchez R., Zhou M.M. The role of human bromodomains in chromatin biology and gene transcription. Curr. Opin. Drug Discov. Devel. 2009, 12(5):659-665.
38. Schultz J., et al. SMART: a web-based tool for the study of genetically mobile domains. Nucleic Acids Res. 2000, 28(1):231-234.
39. Xi Q., et al. A poised chromatin platform for TGF-beta access to master regulators. Cell 2011, 147(7):1511-1524.
40. Ivanov A.V., et al. PHD domain-mediated E3 ligase activity directs intramolecular SUMOylation of an adjacent bromodomain required for gene silencing. Mol. Cell 2007, 28(5):823-837.
41. Wysocka J., Allis C., Coonrod S. Histone arginine methylation and its dynamic regulation. Front. Biosci. 2006, 11:344-355.
42. Wysocka J., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006, 442(7098):86-90.
43. Umehara T., et al. Structural implications for K5/K12-di-acetylated histone H4 recognition by the second bromodomain of BRD2. FEBS Lett. 2010, 584(18):3901-3908.
44. Jacobson R., et al. Structure and function of a human TAFII250 double bromodomain module. Science 2000, 288(5470):1422-1425.
45. Vandemark A.P., et al. Autoregulation of the rsc4 tandem bromodomain by gcn5 acetylation. Mol. Cell 2007, 27(5):817-828.
46. Muller S., Filippakopoulos P., Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 2011, 13:e29.
47. Zeng L., et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 2005, 127(8):2376-2377.
48. Sachchidanand, et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 2006, 13(1):81-90.
49. Borah J.C., et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 2011, 18(4):531-541.
50. Filippakopoulos P., et al. Selective inhibition of BET bromodomains. Nature 2010, 468(7327):1067-1073.
51. Nicodeme E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468(7327):1119-1123.
52. Chung C.W., et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 2011, 54(11):3827-3838.
53. Vidler L.R., et al. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 2012, 55(17):7346-7359.
54. Hewings D.S., et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 2011, 54(19):6761-6770.
55. Hewings D.S., et al. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J. Med. Chem. 2013, 56(8):3217-3227.
56. Chung C.W., et al. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J. Med. Chem. 2012, 55(2):576-586.
57. Bamborough P., et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J. Med. Chem. 2012, 55(2):587-596.
58. Gerona-Navarro G., et al. Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: a new class of p53 inhibitors. J. Am. Chem. Soc. 2011, 133(7):2040-2043.
59. Fedorov O., et al. [1,2,4]Triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J. Med. Chem. 2014, 57(2):462-476.
60. Ferguson F.M., et al. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. J. Med. Chem. 2013, 56(24):10183-10187.
61. Seal J., et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 2012, 22(8):2968-2972.
62. Fish P.V., et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J. Med. Chem. 2012, 55(22):9831-9837.
63. Picaud S., et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 2013, 73(11):3336-3346.
64. Mirguet O., et al. Naphthyridines as novel BET Family bromodomain inhibitors. ChemMedChem 2014, 9(3):580-589.
65. Zhao L., et al. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J. Med. Chem. 2013, 56(10):3833-3851.
66. Gehling V.S., et al. Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med. Chem. Lett. 2013, 4(9):835-840.
67. Vidler L.R., et al. Discovery of novel small-molecule inhibitors of brd4 using structure-based virtual screening. J. Med. Chem. 2013, 56(20):8073-8088.
68. Lucas X., et al. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew. Chem. Int. Ed. Engl. 2013, 52(52):14055-14059.
69. Martin M.P., et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 2013, 8(11):2360-2365.
70. Dittmann A., et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 2014, 9(2):495-502.
71. Ciceri P., et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 2014, 10:305-312.
72. Ember S.W., et al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 2014, [Epub ahead of print].
73. Atkinson S.J., et al. The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes. MedChemComm 2014, 5(3):342-351.
74. Zhang G., et al. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J. Med. Chem. 2013, 56(22):9251-9264.
75. Picaud S., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(49):19754-19759.
76. Meslamani J., et al. ChEpiMod: a knowledgebase for chemical modulators of epigenome reader domains. Bioinformatics 2014, [Epub ahead of print].
77. Liu L., et al. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics 2012, 28(16):2205-2206.
78. Shah M.A., et al. ChromoHub V2: cancer genomics. Bioinformatics 2014, 30(4):590-592.
79. Anand P., et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154(3):569-582.
80. Bremner W.J. Contraception for men: a breakthrough new approach. Cell 2012, 150(4):667-668.
81. Matzuk M.M., et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150(4):673-684.
82. Mertz J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(40):16669-16674.
83. Delmore J.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917.
84. Henssen A., et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 2013, 4(11):2080-2095.
85. Wyce A., et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 2013, 4(12):2419-2429.
86. Da Costa D., et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 2013, 3:e126.
87. Ott C.J., et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120(14):2843-2852.
88. Chaidos A., et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014, 123(5):697-705.
89. Puissant A., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3(3):308-323.
90. Bandopadhayay P., et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin. Cancer Res. 2014, 20(4):912-925.
91. Lockwood W.W., et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(47):19408-19413.
92. Zhu J., et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012, 2(4):807-816.
93. Boehm D., et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013, 12(3):452-462.
94. Banerjee C., et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 2012, 92(6):1147-1154.
95. Li Z., et al. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013, 41(1):277-287.
96. Gupta S.S., et al. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol. 2013, 87(23):12721-12736.
97. Sharma A., et al. BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(29):12036-12041.
98. Wang X., et al. Bromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replication. PLoS Pathog. 2012, 8(11):e1003021.
99. Wu X., et al. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor kappaB (NF-kappaB) signaling. J. Biol. Chem. 2013, 288(50):36094-36105.
100. Magrane M., Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011, bar009.
101. Goupille O., et al. BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7. Biochem. Biophys. Res. Commun. 2012, 429(1-2):1-5.
102. Emadali A., et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol. Med. 2013, 5(8):1180-1195.
103. Cheng Z., et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 2013, 19(7):1748-1759.
104. Shimamura T., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 2013, 19(22):6183-6192.
105. Chen C., et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013, 27(18):1974-1985.
106. Wyspianska B.S., et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia 2014, 28(1):88-97.
107. Tolani B., et al. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2013, [Epub ahead of print].
108. Mele D.A., et al. BET bromodomain inhibition suppresses TH17-mediated pathology. J. Exp. Med. 2013, 210(11):2181-2190.
109. Belkina A.C., Nikolajczyk B.S., Denis G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 2013, 190(7):3670-3678.
110. Zhang G., et al. Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 2012, 287(34):28840-28851.
111. Bandukwala H.S., et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(36):14532-14537.
112. Mirguet O., et al. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg. Med. Chem. Lett. 2012, 22(8):2963-2967.
113. Tang X., et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 2013, 183(2):470-479.